Recombinant interleukin-2 - Amoytop Biotech/BioGeneric Pharma
Latest Information Update: 06 Jan 2016
At a glance
- Originator Amoytop Biotech; BioGeneric Pharma
- Developer Amoytop Biotech
- Class Adjuvants; Antineoplastics; Interleukins; Lymphokines
- Mechanism of Action Immunostimulants; Interleukin 2 stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Unspecified
Most Recent Events
- 06 Jan 2016 Clinical trials in Undefined indication in China (unspecified route)